Lipid-Based Delivery of Plant Antidiabetic Agents: Material Design to Clinical Translation

Fig 2. Phytochemical Target Mechanisms

1. Flavonoids (e.g., Quercetin, Morin, Rutin)

Flavonoids act as powerful antioxidants that neutralize reactive oxygen species (ROS), preserving pancreatic β-cell viability and architectural integrity. At the receptor level, specific molecules like morin activate insulin receptor autophosphorylation, improving downstream metabolic pathways and reducing endoplasmic reticulum (ER) stress. Others show direct competitive inhibition against mammalian carbohydrate-digesting enzymes.

 2. Alkaloids (e.g., Trigonelline, Berberine)

Alkaloids regulate glucose profiles through multiple structural pathways. Trigonelline, found in defatted fenugreek fractions, mediates strong glucose-lowering effects. This class systematically upregulates insulin receptor sensitivity, promotes endogenous pancreatic insulin secretion, and blocks dietary intestinal glucose absorption.

 3. Terpenoids and Saponins (e.g., Gymnemic Acids, Ginsenosides)

Ginsenosides (triterpene saponins) operate across multiple target organs: Ginsenovide Rb2 reduces excessive hepatic gluconeogenesis, while Rb1, Rg3, and Compound K enhance peripheral glucose clearance in skeletal muscle and adipose tissue by upregulating the expression and membrane translocation of GLUT-1 and GLUT-4 transporters. Thermally degraded saponins like ginsenoside Rg3 also stimulate glucagon-like peptide-1 (GLP-1) release from enteroendocrine cells. Gymnemic acids induce reversible cell permeabilization in pancreatic islets to stimulate endogenous insulin release, while simultaneously blocking small-intestinal glucose transport and hepatic glycogenolysis.

4. Polyphenols and Tannins (e.g., Charantin, Epicatechin, Gallic Acid)

These molecules prevent secondary microvascular complications like cataracts through systemic free radical scavenging. Molecules like epicatechin promote pancreatic islet regeneration, while broader polyphenolic fractions block α-amylase and α-glucosidase pathways, flattening postprandial glucose absorption spikes(6–8).

Target Profiles of Core Botanicals (9–12)

Table 1. Properties of Phytoconstituents

Physicochemical, Pharmacokinetic, and Stability Obstacles

Translating crude botanicals or isolated phytochemicals into reliable clinical therapies is hindered by several major biopharmaceutical limitations:

1. Large Molecular Mass and High Polarity: Many potent plant metabolites (e.g., polar glycosides, high-molecular-weight tannins) possess structures that prevent them from passively crossing the lipid-rich biological membranes of the intestinal mucosa, restricting absorption.

2. Gastrointestinal Instability: Orally ingested phytochemicals face rapid destruction inside the strongly acidic environment of the stomach and undergo extensive metabolic modification by native gut microflora or digestive enzymes.

3. Poor Aqueous Solubility: Lipophilic terpenoids and volatile fractions dissolve poorly within aqueous gastrointestinal fluids, causing highly erratic dissolution profiles and low baseline plasma availability.

4. Rapid Systemic Clearance:  The combination of low intestinal absorption, high pre-systemic clearance, and short metabolic half-lives prevents molecules from maintaining therapeutic plasma levels unless high, frequent doses are administered—which increases the risk of local gastrointestinal side effects(14).

To resolve these limitations, modern formulation design leverages specialized delivery networks to encapsulate and shield these molecules, improving their metabolic stability and biological absorption.

3. LIPID-BASED DRUG DELIVERY PLATFORMS: CORE STRUCTURAL PRINCIPLES

Lipid-based drug delivery systems (LBDDS) function as biomimetic nanoscale carriers. They present a superior safety profile compared to synthetic polymer matrices due to their high biocompatibility and biodegradability, as they utilize lipid components identical to endogenous biological membranes. By completely encapsulating active payloads, these systems insulate them from external degradation, modulate their release kinetics, and unlock versatile administration routes (oral, transdermal, mucosal, and parenteral)(15,16).

Structural Classification of Lipid Carriers

Liposomes

Spherical vesicles featuring an aqueous core enclosed by one or more concentric phospholipid-cholesterol bilayers. This unique structural layout allows them to concurrently host hydrophilic compounds in the internal water compartment and lipophilic drugs within the middle hydrophobic bilayers. Conventional configurations can suffer from self-leakage or structural aggregation, which is typically managed using stabilizers like DSPE-MPEG 2000(17).

Solid Lipid Nanoparticles (SLNs)

Particulate carriers composed of a solid hydrophobic lipid core (e.g., tristearin or purified stearic acid) stabilized by an outer surfactant layer. Because the core lipid remains strictly solid at both room and body temperatures, SLNs form a highly ordered crystalline matrix that excels at loading lipophilic molecules (log P > 3). When applied to the skin, they form a dense, occlusive film that restricts transepidermal water loss. However, their highly ordered solid lattices can undergo crystal restructuring during storage, potentially squeezing the internal matrix and causing drug expulsion.

Nanoemulsions

Advanced, submicron colloidal dispersions consisting of a liquid lipid core wrapped within a surfactant monolayer shell. Composed of oils, surfactants, and water-soluble co-solvents, they are highly effective at enhancing the solubility, intestinal dissolution rate, and oral bioavailability of intensely hydrophobic compounds while shielding them from first-pass hepatic elimination.

 Nanostructured Lipid Carriers (NLCs)

Developed as second-generation lipid nanoparticles to overcome the drug expulsion flaws of SLNs. Their core matrix is formed by intentionally blending solid lipids with liquid oils (e.g., oleic acid, medium-chain triglycerides). This fluid-fat blend yields a highly disorganized, less-ordered crystalline framework with numerous imperfect nano-compartments that accommodate higher drug payloads and prevent leakage. They are classified into:

Type 1 (Imperfect): High drug loading capacity paired with quick release profiles.

Type 2 (Amorphous): Prevents crystallization completely.

Type 3 (Multiple): Microscopic liquid oil droplets dispersed inside a solid fat matrix(18,19).

Ethosomes

Modified liposomal architectures containing high concentrations of ethanol (20%-50%) alongside phospholipids and water. This hydro-ethanolic solution imparts exceptional elasticity and a net negative charge to the vesicle membrane, facilitating continuous transdermal flux via a dual mechanism:

1. The Ethanol Effect: Disrupts and fluidizes the highly organized intercellular lipid bilayers of the stratum corneum, opening narrow pathways.

2. The Ethosome Effect: Malleable vesicles deform to squeeze through these newly opened channels into deep epidermal and dermal layers, fusing with cell membranes to release their payload(20).

Transferosomes

Ultra-deformable vesicular systems containing phospholipids combined with a single-chain surfactant acting as an edge activator. The edge activator destabilizes the lipid bilayer at specific stress points, making the vesicle flexible and highly responsive to osmotic forces. Applied non-occlusively to the skin, transferosomes respond to the natural hydration gradient, changing shape to pass intact through narrow skin pores that would stop conventional liposomes.

Physicochemical Framework of Lipid Carriers

The loading capacity, encapsulation parameters, and transport dynamics of LBDDS are governed by precise chemical principles:

Lipophilicity: Hydrophobic compounds (log P > 3) partition seamlessly into the internal fatty acid domains of SLNs, NLCs, and nanoemulsions, ensuring high payload capacity and diffusion-controlled release.

Amphiphilicity: Phospholipids feature a zwitterionic hydrophilic polar head group and two lipophilic fatty acid acyl chains. In aqueous media, they spontaneously self-assemble into closed bilayers to hide their hydrophobic tails from water, creating distinct compartments that can carry polar and non-polar drugs simultaneously.

Encapsulation & Charge Dynamics: Perfect, uniform solid fats can push out drugs over time, whereas adding liquid oils disrupts molecular packing to maximize encapsulation space. Furthermore, introducing a positive surface charge (zeta potential) creates strong electrostatic attraction with negatively charged biological membranes, increasing skin adhesion and cellular internalization(15,21).

4. BIOAVAILABILITY AND STABILITY IMPROVEMENTS FOR PLANT ACTIVES

1. Solubility Enhancement: Embedding molecules like curcumin or quercetin into lipid bilayers or disorganized NLC cores significantly improves their saturation solubility and water dispersion, preventing the particle aggregation seen with raw botanical extracts.

2. Protection from Degradation: Lipid nanocarriers form a protective physical barrier that completely insulates plant actives from acid and enzymatic hydrolysis in the stomach. For photo-sensitive molecules like curcuminoids, encapsulation in an SLN matrix keeps 88%-96% of the active components completely intact after six months of storage.

3. Bioavailability Multipliers: In animal models, curcumin-loaded SLNs demonstrate a 39- to 155-fold increase in plasma bioavailability compared to free suspensions. Quercetin-loaded SLNs provide a 5-fold increase in bioavailability by shifting the primary absorption zone to the small intestine. Puerarin-loaded SLNs achieve a 3-fold increase in absolute bioavailability with a shortened T_max. For skin applications, vesicular ethosomes increase the tissue deposition of psoralen by 6.56-fold, while curcumin delivered via nanoemulsions improves local epidermal drug accumulation by 2.4- to 3.3-fold(22).

5. FORMULATION DESIGN, OPTIMIZATION, AND INDUSTRIAL SCALE-UP

Developing a stable, clinically viable LBDDS requires a structured formulation workflow, moving from preformulation profiling to continuous industrial manufacturing.

5.1 Preformulation and Excipient Selection

Rational formulation begins by establishing the physicochemical profile of the plant active, tracking its intrinsic aqueous solubility, ionization constant (pKa), partition coefficient (log P/log D), and solid-state compatibility with lipid matrices.

Mapping the pH-solubility curve predicts precipitation risks across the gastrointestinal tract, while tracking the pKa reveals the ratio of ionized to unionized species at gastric (~pH 1.2) versus intestinal (~pH 6.8) conditions, directly influencing encapsulation strategies. High log P compounds (>3) are assigned to self-emulsifying or solid lipid cores, while lower log P fractions require vesicular assembly or phospholipid complexation (phytosomes). Solid-state interactions are screened using FTIR, DSC, and XRD to prevent phase separation or drug degradation in the final vehicle.

Excipient composition is guided by the Lipid Formulation Classification System (LFCS), which groups formulations from Type I (pure oils) to Type IV (pure hydrophilic surfactants and co-solvents).

Table 2. Excipient selection

Surfactant selection balances Hydrophilic-Lipophilic Balance (HLB) values against behavior during gastrointestinal lipolysis. High-HLB surfactants promote spontaneous emulsification into nanoscale droplets (<200 nm) upon contact with gastric fluids. Surfactants like Vitamin E TPGS are widely utilized because they function as both structural stabilizers and active p-gp efflux inhibitors, directly boosting oral absorption(23,24).

5.2 Processing Methodologies and Loading Strategies(25,26)

Fig 3. Preformulation and processing methodologies

Processing methods dictate the internal structure, droplet size distribution, and encapsulation efficiency of the lipid carrier. These methods are divided into high-energy and low-energy techniques:

High-Energy Methods: High-Pressure Homogenization (HPH) and Microfluidization apply intense shear, cavitation, and impact forces to break down macro-emulsions into uniform nano-emulsions or solid lipid matrices. While highly efficient for scalable manufacturing, they generate local temperature spikes that can degrade heat-sensitive phytochemicals. Ultrasonication is suitable for rapid bench-scale screening but carries risks of titanium probe shedding and uneven energy distribution.

Low-Energy Methods: Thin-Film Hydration (TFH) dissolves lipids and actives in an organic phase, evaporates it into a thin film, and hydrates it with an aqueous buffer. This method achieves high encapsulation for amphiphilic compounds but requires secondary extrusion for uniform particle sizing. Phase Inversion Temperature (PIT) and Solvent Diffusion utilize the chemical energy of the system; by adjusting temperature or shifting water-miscible solvents, the system spontaneously reorganizes into nanoscale structures under gentle stirring(27).

Loading Architecture

Encapsulating plant antidiabetics requires unique loading strategies based on whether the active payload is a complex whole-plant extract or an isolated pure molecule:

Fig 4. Phytochemical loading

Complex crude extracts contain mixtures of competing polarities, resulting in lower overall encapsulation efficiency due to competition for space within the lipid matrix. Pure isolated compounds behave predictably, enabling formulators to tailor the lipid matrix to the molecule's specific log P. Highly lipophilic compounds embed deeply within the fatty acid core of SLNs/NLCs, whereas weakly hydrophobic compounds position themselves at the surfactant-water interface (surface adsorption), which can lead to a rapid initial burst release rather than a sustained release profile. For highly hydrophilic compounds, reversibly coupling the active to a fatty acid chain via an ester or amide linkage creates a lipophilic lipid-prodrug conjugate that dissolves efficiently into the lipid carrier and releases the parent drug via endogenous esterases after crossing the intestinal barrier(28,29).

5.3 Scale-Up and Manufacturing Validation

Fig 5. Scale up of LNP

Transitioning from small lab-scale batches to industrial production introduces significant chemical engineering challenges. Traditional techniques like thin-film hydration are limited by batch volume limits and high batch-to-batch variability. Industrial production relies on continuous manufacturing setups, such as cross-flow microfluidic chips or multi-stage continuous high-pressure homogenizers, to maintain consistent Critical Quality Attributes (CQAs).

During scale-up, operators must strictly control engineering variables (Critical Process Parameters, or CPPs), including volumetric flow rate ratios in microfluidic channels, precise homogenization pressures, and cooling/solidification rates during lipid crystallization. Standardized marker assays must be established to manage the natural chemical variability of plant extracts and guarantee consistent drug-to-lipid ratios. Finally, complete removal of residual organic solvents (e.g., chloroform, methanol) requires industrial-scale vacuum drying, spray drying, or lyophilization to strictly satisfy international regulatory thresholds (ICH Q3C)(21,30,31).

 6. BIOLOGICAL EVALUATION AND MECHANISTIC STUDIES(32)

Validating the performance of plant-derived antidiabetic LBDDS requires a systematic, multi-tiered testing hierarchy, transitioning from in vitro characterization to in vivo pharmacokinetic and biodistribution tracking.

6.1 In Vitro Characterization Models

Physicochemical Characterization: Evaluation of key CQAs begins with Dynamic Light Scattering (DLS) to determine mean particle size (Z-average) and Polydispersity Index (PDI), where a PDI <0.3 indicates a highly stable, monodisperse population. Surface charge is verified via zeta potential, where values outside the range confirm strong electrostatic repulsion that prevents particle aggregation. High-resolution imaging (TEM, SEM) is utilized to confirm spherical morphology and rule out co-existing structures. Encapsulation Efficiency (EE%) and Drug Loading (DL%) must be systematically quantified.

Solid-State Properties: DSC and XRD track lipid crystallinity and polymorphic phase transitions (e.g., transition from highly ordered β-forms to less ordered α or β polymorphs), confirming the presence of an imperfect matrix desirable for preventing drug expulsion. FTIR spectroscopy tracks specific vibrational frequencies to confirm the chemical integrity of the active and verify the absence of incompatible drug-excipient chemical interactions(31,33).

Dissolution Metrics: Drug release is mapped using the dialysis bag method, Franz diffusion cells, or flow-through setups (USP Dissolution Apparatus 4). To generate predictive in vitro-in vivo correlations (IVIVC), standard USP setups are modified with biorelevant media—such as Fasted State (FaSSIF) or Fed State (FeSSIF) Simulated Intestinal Fluids—to replicate physiological lipid digestion, lipolysis, and micellar solubilization.

Permeability & Cellular Safety: Human epithelial Caco-2 cell monolayers serve as the benchmark for forecasting intestinal mucosal permeability, tracking apparent permeability coefficients driven by cell-membrane fluidization or the direct inhibition of ABC efflux transporters (P-gp) by lipid surfactants. Enzyme stability assays expose formulations to simulated gastric/pancreatic enzymes to verify that the lipid core physically insulates sensitive botanicals from premature breakdown.

Cell-Based Functional Assays: Insulin secretion kinetics are tracked in pancreatic β-cell lines (RIN-m5F, MIN6) to verify changes in glucose-stimulated insulin secretion (GSIS). Peripheral glucose uptake is assayed in skeletal muscle cell lines (C2C12 myotubes) using fluorescent glucose analogues (2-NBDG) to quantify insulin-mimetic transport. Cultured 3T3-L1 adipocytes provide insights into lipid transport and the upregulation of PPARγ(34–36).

6.2 Ex Vivo and In Situ Models

Intestinal Perfusion (In Situ): Single-Pass Intestinal Perfusion (SPIP) models in rodents maintain an active, intact mesenteric blood supply and mucus layers. These studies confirm that lipid carriers significantly increase the effective permeability (Peff) of poorly soluble compounds across the natural intestinal barrier compared to unformulated active controls.

Skin Permeation (Ex Vivo): Franz diffusion cells utilizing excised human or porcine skin are deployed to evaluate transdermal systemic systems or localized wound-healing configurations. Highly elastic vesicular assemblies (transfersomes) and lipid nanoparticles blend directly into the stratum corneum, temporarily reorganizing extracellular lipid structures to achieve a high steady-state flux (J_ss) into the deep dermal capillaries.

6.3 In Vivo Pharmacokinetics, Lymphatic Transport, and Biodistribution

Preclinical validation requires tracking plasma concentration-time curves (Cmax, Tmax, AUC) in induced diabetic animal models, where lipid nanoformulations systematically improve absolute oral bioavailability (F%) for BCS Class II and IV phytochemicals by keeping them pre-solubilized within the gut lumen(37).

A core advantage of utilizing lipid vehicles containing long-chain triglycerides (LCTs) is their ability to access the intestinal lymphatic transport pathway, bypassing first-pass hepatic elimination:

Fig 6. Physiological fate of lipid carried actives

When highly lipophilic plant compounds (log P > 5), with high solubility in triglycerides) are co-administered with LCTs, they trigger the assembly of chylomicrons within the enterocyte's endoplasmic reticulum and Golgi apparatus. Because of their large size, these chylomicron-phytochemical complexes are selectively absorbed into the highly permeable lacteals of the intestinal lymphatic system rather than entering the blood capillaries of the portal vein. By routing through the thoracic duct directly into the systemic circulation, the active antidiabetic compounds completely bypass first-pass hepatic metabolism. This minimizes pre-systemic clearance, extends the plasma half-life (t_1/2), and maintains steady, long-term glycemic control(38,39).

6.4 Pharmacodynamics and Safety Profile

In Vivo Pharmacodynamics: Enhanced systemic absorption leads to sustained plasma concentrations of active phytochemicals, downregulating postprandial glucose spikes via the competitive inhibition of intestinal carbohydrate-digesting enzymes (α-glucosidase and α-amylase). At the cellular level, these protected formulations promote deep tissue penetration into skeletal muscle and adipose tissues, maintaining the activation of the AMPK pathway and triggering the translocation of GLUT-4 vesicles to the cell membrane to reverse insulin resistance. Steady bioavailability prevents the structural collapse of the islets of Langerhans under glucotoxic conditions, preserving β-cell morphology and maintaining baseline GSIS. Furthermore, LBDDS exhibit powerful antioxidant properties by downregulating intracellular lipid peroxidation, and suppress inflammation by inhibiting the NF-κB pathway, which reduces the expression of pro-inflammatory cytokines like TNFα and IL-6.

Safety and Toxicity Metrics: Acute oral toxicity tests establish the Median Lethal Dose (LD₅₀), which shifts higher upon lipid encapsulation due to the lower peak tissue toxicity of shielded drugs. Subchronic toxicity profiles (repeated daily oral dosing for 28 to 90 days) monitor body weight, hematological parameters, and biomarkers for hepatic (ALT, AST) and renal (creatinine, BUN) function to confirm the metabolic safety of the lipid vehicles. Complement activation tests ensure that the nanoformulations do not trigger unexpected hypersensitivity reactions; using highly purified, naturally derived lipids avoids the immune clearance or complement-activation-related pseudoallergy (CARPA) issues linked to synthetic coatings(40).

7. CASE STUDIES OF PHYTOCHEMICAL-LOADED LIPID FORMULATIONS

Curcumin-Loaded Solid Lipid Nanoparticles (SLNs)

The Bioavailability Hurdle: Curcumin exhibits extraordinary multi-targeted therapeutic potential but possesses sub-microgram water solubility, faces rapid crystalline degradation in the intestinal lumen, and undergoes extensive phase-II glucuronidation in the liver.

Lipid Vehicle Strategy: Encapsulation within SLNs using biocompatible solid lipids (e.g., Compritol 888 ATO) stabilized by a hydrophilic surfactant coat (e.g., Poloxamer 188 / Tween 80).

In Vivo Outcomes: In vivo oral dosing demonstrates a 12- to 15-fold increase in absolute bioavailability compared to unformulated native curcumin suspended in water. In STZ-induced diabetic rats, oral administration significantly restores fasting blood glucose and lowers HbA1c. Nanoscale lipid particle accumulation within the vascular endothelium yields a profound reduction in oxidative myocardial remodeling and tissue fibrosis, offering protection against diabetic cardiomyopathy(41,42).

Chitosan-Coated Berberine Solid Lipid Nanoparticles

The Bioavailability Hurdle: The alkaloid berberine is a potent activator of AMPK, but its absolute oral bioavailability is lower than 1% because it dissolves poorly in physiological lipids, possesses a strong positive charge that limits mucosal absorption, and is actively rejected by intestinal P-gp efflux transporters.

Lipid Vehicle Strategy: Core encapsulation of berberine into a lipid nanoparticle matrix, surface-modified with a coating of the mucoadhesive polymer chitosan.

In Vivo Outcomes: Excipients physically mask berberine from P-gp detection while the cationic chitosan shell electrostatically binds to the negatively charged intestinal mucosa, extending intestinal residence time (T_max) and maximizing transcellular influx. In vivo screening in models of gestational diabetes and db/db mice reveals that low-dose Berberine-SLNs significantly lower HOMA-IR scores, halt hepatic triglyceride deposition (steatosis), and normalize liver antioxidant enzymes far more effectively than unformulated, high-dose native berberine(43) (44).

Quercetin-Loaded Self-Nanoemulsifying Drug Delivery Systems (SNEDDS)

The Bioavailability Hurdle: The flavonoid quercetin acts as a competitive inhibitor of α-glucosidase and α-amylase to control postprandial glucose spikes, but its clinical development is restricted by poor water solubility and aggressive first-pass hepatic metabolism.

Lipid Vehicle Strategy: Formulation into isotropic anhydrous mixtures of long-chain/medium-chain triglycerides, surfactants, and co-surfactants that spontaneously emulsify into ultra-fine droplets (<50 nm) upon contact with gastric fluids.

In Vivo Outcomes: The massive interfacial surface area maintains quercetin in a pre-solubilized state within the gut lumen, while long-chain lipid carrier excipients trigger enterocyte chylomicron assembly, forcing the absorbed droplets into the intestinal lymphatic pathway. In vivo oral glucose tolerance tests in diabetic rats confirm that Quercetin-SNEDDS achieve smooth, immediate postprandial glycemic control, preserve pancreatic β-cell morphology within the islets of Langerhans, and slow down microvascular complications, specifically mitigating diabetic nephropathy(45,46).

8. CLINICAL TRANSLATION, REGULATORY STATUS, AND TECHNICAL GAPS

 8.1 Clinical Data and Regulatory Landscapes

A significant translational gap persists between rodent data and human confirmation. Human trials exploring lipid-encapsulated plant nanocarriers remain limited, with active registered clinical trials focusing primarily on Nano-Curcumin preparations (micellar or lipid-lecithin complexes). These early clinical evaluations confirm that nano-lipid delivery significantly stabilizes fasting blood glucose and improves serum lipid profiles (lowering LDL-C and free fatty acids) in patients diagnosed with metabolic syndrome and Type 2 Diabetes, without inducing gastrointestinal distress(42,47,48).

Regulatory approval enforced by the FDA and EMA requires navigating a demanding dual framework:

Fig 7. Regulatory compliance